@article{oai:soar-ir.repo.nii.ac.jp:00003826,
 author = {Yoneda,  Suguru and Umemura,  Takeji and Joshita,  Satoru and Ichijo,  Tetsuya and Matsumoto,  Akihiro and Yoshizawa,  Kaname and Katsuyama,  Yoshihiko and Ota,  Masao and Tanaka,  Eiji},
 issue = {6},
 journal = {HEPATOLOGY RESEARCH},
 month = {Jun},
 note = {Aim: Serum chemokine levels and amino acid substitutions in the interferon-sensitivity determining region (ISDR) and core region have been associated with treatment outcome of pegylated interferon and ribavirin therapy in genotype 1 hepatitis C virus (HCV)-infected patients. The present study was conducted to clarify the association between serum chemokines and treatment outcome in patients with chronic HCV-1 infection in a Japanese cohort. Methods: A total of six serum chemokines were quantified before, during and after pegylated interferon and ribavirin treatment in 79 genotype 1 chronic HCV patients using a multiple bead array system. Viral ISDR and core region variants were determined by direct sequencing. Results: The baseline serum levels of eotaxin, IP-10 and RANTES were significantly higher in chronic HCV patients than in controls. High levels of eotaxin and macrophage inflammatory protein (MIP)-1 beta before therapy and more than two mutations in the ISDR were associated with a sustained virological response, and patients with more than two mutations in the ISDR also had significantly higher MIP-1 beta levels. Receiver-operator curve analysis showed a 77% sensitivity and 73% specificity for predicting an SVR using MIP-1 beta values. Conclusion: Serum MIP-1 beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR., Article, HEPATOLOGY RESEARCH. 41(6):587-593 (2011)},
 pages = {587--593},
 title = {Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C},
 volume = {41},
 year = {2011}
}